You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
A novel RF coil and incubator for reducing acoustic noise in neonatal MRI
SBC: NeoView, Inc. Topic: NICHDPROJECT SUMMARY In this Phase I Small Business Technology TransferSTTRprojecta team of researchers at Cincinnati Childrenandapos s Hospital Medical CenterCCHMCwill work with the engineering team at NeoViewIncto design and build novel body coil and incubator prototypes for aTesla Neonatal Intensive Care UnitNICUMRI systemThese components will play a central role in NeoViewandapos s neonatal MRI pro ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's Disease
SBC: Amprion, Inc. Topic: NIAABSTRACT This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a test for high sensitive detection of tau oligomers in biological fluidswhich could be used for the biochemical diagnosis of Alzheimerandapos s diseaseADand related tauopathiesAD is the most common dementia in the elderly population and one of the leading causes of death in the develop ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeting glioblastoma stem-like cells with custom-designed viral vectors
SBC: Lacerta Therapeutics, Inc. Topic: 102Abstract GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneit ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
An Engineered Nanoimmunotherapy for Melanoma
SBC: IMMUNOBLUE, LLC Topic: NCIPROJECT SUMMARY Melanoma is one of the most prevalent cancers and is estimated to account for overdeaths inin the United States aloneAlthough highly curable when detected earlytheyear survival rates decline precipitously for patients with regionaland metastaticmelanoma indicating a lack of efficacy of conventional therapiesand a strong need for novel therapies for this patient populationIn respons ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Brain Targeting Nanoparticle for Drug Delivery in Traumatic Brain Injury
SBC: WEINBERG MEDICAL PHYSICS, INC. Topic: DHA18A001There is an urgent need to bypass or cross the blood brain barrier (BBB) to deliver drugs for TBI treatment. This project aims to develop targted intranasally delivered, magnetically propulsed, and targted nanoparticles for traumatic brain injury (TBI). In Phase I, we will demonstrate the design, fabrication, and in vitro characterization of proposed drug laden magnetic nanoparticles as well as co ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics
SBC: SAB CAPRA, LLC Topic: NIAIDProject Summary A research plan is proposed to engineer goats that produce fully human immunoglobulinThese animals will be evaluated as a candidate platform system for production of both targeted therapeutic immunoglobulin as well as reagent antibodies for standards and controls of serological assays of human clinical samplesPrevious studies have demonstrated that ungulates such as cattle can prod ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Oxygen Production and Delivery on Demand
SBC: GLOBAL RESEARCH & DEVELOPMENT INC Topic: DHA17B005This proposal is in response to the Defense Health Agency 2017 Phase I SBIR topic 17B-005.The approach is the use of a membrane oxygen pump using newly developed nano-thickness membranes with all the layers less than 1 micron total.Nanometer thickness membranes enable more oxygen output per surface area at temperatures of 300-600 C than current state-of-the -art 600-800 C membranes that are 50-300 ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Position tracking and mobility assessment system for indoor monitoring of elders
SBC: EMBEDRF LLC Topic: NIADESCRIPTION (provided by applicant): The long term objective of this project is to enable elderly persons to independently live within their own homes later into their lives with the assurance that their safety and well-being can be remotely monitored by health care professionals. A critical component of remote health care monitoring is physically tracking the location of the patient within a livi ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Development of monoclonal catalytic antibodies for HIV immunotherapy
SBC: COVALENT IMMUNOLOGY PRODUCTS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): We have raised murine monoclonal antibodies (MAbs) to a conserved region of the CD4 binding site of gp120 (CD4bs) that neutralize genetically diverse HIV strains. The MAbs have a novel mechanism of action. They hydrolyze multiple molecules of gp120, thereby imparting MAb increased biological efficacy. About 10% of HIV infected subjects develop resistance to cur ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health